Abstracts tagged "Juvenile arthritis and treatment"

Abstract Number: 978 • 2018 ACR/ARHP Annual Meeting
Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis
Gerd Horneff¹, Ivan Foeldvari², Ralf Trauzeddel³, Toni Hospach⁴, Kirsten Minden⁵, Hans-Iko Huppertz^6,7 and Ariane Klein⁸, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Hamburger Zentrum fur, Kinder-und Jugendrheumatologie, Hamburg, Germany, ³Helios Clinics, Berlin, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁶Prof Hess Clinic, Bremen, Germany, ⁷Prof. Hess Childrens Hospital, Bremen, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most prevalent chronic diseases of childhood and adolescence. Evidence suggests that early effective treatment is important…
Abstract Number: 284 • 2014 ACR/ARHP Annual Meeting
Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE)– Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Idiopathic Arthritis
S.J. Vastert¹, Victor Boom², Jordi Anton³, Tamás Constantin⁴, Pavla Dolezalova⁵, Gerd Horneff⁶, Pekka Lahdenne⁷, Bo Magnusson⁸, Kirsten Minden⁹, K. Nistala¹⁰, Pierre Quartier¹¹, Ingrida Rumba-Rozenfelde¹², Nicolino Ruperto¹³, Vanessa Remy Piccolo¹⁴, Ricardo A. G. Russo¹⁵, Yosef Uziel¹⁶, Carine Wouters¹⁷, Alberto Martini¹⁸, Angelo Ravelli¹⁹, Helen Foster²⁰ and Nico Wulffraat²¹, ¹Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ⁴Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁵Paediatric Rheumatiology unit, 1st Faculty of Medicine, General University Hospital, Prague, Czech Republic, ⁶Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁷Paediatrics, Helsinki University Central Hospital, Helsinki, Finland, ⁸Pediatric Rheumatology, Astrid Lindgren Children's Hospital, Stockholm, Sweden, ⁹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ¹⁰Centre for Rheumatology, University College London, London, United Kingdom, ¹¹Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹²University of Latvia, Riga, Latvia, ¹³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ¹⁴Pediatric Rheumatology, Hopital Necker Enfants Malades, Paris, France, ¹⁵Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ¹⁶Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ¹⁷University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ¹⁸Istituto Giannina Gaslini, Genova, Italy, ¹⁹University of Genova, Genova, Italy, ²⁰Newcastle University, Newcastle, United Kingdom, ²¹Paediatric Immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic pediatric rheumatic diseases (PRD). As is the case for most PRD's, evidence-based guidelines…
Abstract Number: 1170 • 2012 ACR/ARHP Annual Meeting
Folate Usage in Methotrexate -Treated Juvenile Idiopathic Arthritis Patients Is Inconsistent and Highly Variable
Gil Amarilyo¹, Ornella J. Rullo², Deborah K. McCurdy³, Jennifer M.P. Woo¹ and Daniel Furst⁴, ¹Pediatrics/Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ²Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA
Background/Purpose: Low-dose weekly methotrexate (MTX) is the first-choice second-line drug in the treatment of juvenile idiopathic arthritis (JIA). Folate (as either Folic acid (FA) or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].